Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene falls after earnings

CELG fell $5.96 to $64.22 on 21.6 million shares on Thursday after reporting 3Q07 revenues that missed the Street

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE